DK200900016A - Stabiliserede insulinlignende vækstfaktorpolypeptider - Google Patents
Stabiliserede insulinlignende vækstfaktorpolypeptider Download PDFInfo
- Publication number
- DK200900016A DK200900016A DK200900016A DKPA200900016A DK200900016A DK 200900016 A DK200900016 A DK 200900016A DK 200900016 A DK200900016 A DK 200900016A DK PA200900016 A DKPA200900016 A DK PA200900016A DK 200900016 A DK200900016 A DK 200900016A
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- precursor protein
- peptide
- deleted
- human animal
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims 5
- 102000013275 Somatomedins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 52
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 239000002243 precursor Substances 0.000 claims 22
- 235000018102 proteins Nutrition 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 11
- 241000283690 Bos taurus Species 0.000 claims 6
- 241001494479 Pecora Species 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 241000251468 Actinopterygii Species 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 241000283707 Capra Species 0.000 claims 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 4
- 241000282887 Suidae Species 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 241000282326 Felis catus Species 0.000 claims 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 3
- 241000283073 Equus caballus Species 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 241000282898 Sus scrofa Species 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 235000013365 dairy product Nutrition 0.000 claims 2
- 235000013372 meat Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical group 0.000 claims 2
- 244000144977 poultry Species 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
Claims (44)
1. Polypeptid omfattende et ikke-humant animalsk IGF-1-precursorprotein, hvor spaltningen af E-peptidet fra IGF-1 med en protease er formindsket ved modifikation af precursorproteinet.
2. Polypeptid ifølge krav 1, hvor det ikke-humane animalske IGF-1-precursorprotein stammer fra en ikke-human hvirveldyrsart.
3. Polypeptid ifølge krav 2, hvor den ikke-humane hvirveldyrsart er valgt blandt en mus, en rotte, en ko, en gris, en hest, et får, en ged, en fugl, en hund, en kat eller en fisk.
4. Polypeptid ifølge ethvert af kravene 1-3, hvor precursorproteinet omfatter Ea-peptidet.
5. Polypeptid ifølge krav 4, hvor Ea-peptidet er valgt fra en ikke-human animalsk sekvens i fig. 8A.
6. Polypeptid ifølge ethvert af kravene 1-3, hvor precursorproteinet omfatter Eb-peptidet.
7. Polypeptid ifølge krav 6, hvori Eb-peptidet er valgt fra en ikke-human animalsk sekvens i fig. 9a.
8. Polypeptid ifølge krav 6 eller 7, hvor de sidste syv C-terminale aminosyrer i Eb er detekteret.
9. Polypeptid ifølge ethvert af kravene 1-3, hvor precursorproteinet omfatter Ec-peptidet.
10. Polypeptid ifølge krav 9, hwor Ec er valgt fra en ikke-human animalsk sekvens i fig. 10a.
11. Polypeptid ifølge ethvert af de foregående krav, hvor G1 i precursorproteinet er deleteret eller muteret.
12. Polypeptid ifølge ethvert af de foregående krav, hvor P2 i precursorproteinet er deleteret eller muteret.
13. Polypeptid ifølge ethvert af de foregående krav, hvor E3 i precursorproteinet er deleteret eller muteret.
14. Polypeptid ifølge ethvert af de foregående krav, hvor R36 i precursorproteinet er deleteret eller muteret.
15. Polypeptid ifølge ethvert af de foregående krav, hvor R36 er muteret til alanin.
16. Polypeptid ifølge ethvert af de foregående krav, hvor R37 i precursorproteinet er deleteret eller muteret.
17. Polypeptid ifølge ethvert af de foregående krav, hvor R37 er muteret til alanin.
18. Polypeptid ifølge ethvert af de foregående krav, der yderligere omfatter den N-bundne glycosyleringskonsensussekvens NXS/T.
19. Eb-polypeptidet ifølge krav 6, der yderligere omfatter aminosyrer 93-102 i Ea indsat mellem aminosyrer N95 og T96 i Eb.
20. Polypeptid ifølge ethvert af de foregående krav, der yderligere omfatter et oligosaccharid covalent bundet til en aminosyresideksede i precursorproteinet.
21. Polypeptid ifølge krav 20, hvor oligosaccharidet er covalent bundet til en argininsidekæde i precursorproteinet.
22. Polypeptid ifølge ethvert af de foregående krav, hvor en rest af precursorproteinet er erstattet med en ikke-naturlig aminosyre.
23. Polypeptid ifølge krav 22, hvor den ikke-naturlige aminosyre omfatter en acetyleneller azidogruppe.
24. Polypeptid ifølge ethvert af de foregående krav, der yderligere omfatter en poly(ethylenglycol)/del covalent bundet til en sidekæde i precursorproteinet.
25. Polypeptid ifølge ethvert af de foregående krav, der yderligere omfatter et yderligere E-peptid forbundet til C-terminalen i precursorproteinet.
26. Polypeptid, derfra N-terminal til C-terminal omfatter et IGF-1-precursorprotein omfattende et første Eb-peptid, hvor G1, P1 og E1 erdeleteret, R36 og 37 er delete ret, R71 og S72 er deleteret, og de sidste syv C-terminale aminosyrer i det første Eb-peptid er deleteret, et andet Eb-peptid, hvor R71, S72 og de sidste syv C-terminale aminosyrer i det andet Eb-peptid er deleteret, et tredje Eb-peptid, hvor R71, S72 og de sidste syv C-terminale aminosyrer i det tredje Eb-peptid er deleteret, og et fjerde Eb-peptid, hvor R71 og S72 er deleteret.
27. Polypeptid ifølge ethvert af kravene 1-26, hvor R71 eller S72 i precursorproteinet er deleteret eller muteret.
28. Polypeptid indeholdende et ikke-humant animalsk IGF-2-precursorprotein, hvor spaltningen af E-peptidet fra IGF-2 med en protease er formindsket ved modifikation af precursorproteinet.
29. Polypeptid ifølge krav 28, hvor den ikke-humane hvirveldyrsart er valgt blandt en mus, en rotte, en ko, en gris, en hest, et får, en ged, en fugl, en hund, en kat eller en fisk.
30. Polypeptid ifølge ét af kravene 28-39, hvor precursorproteinet omfatter E-peptidet i IGF-2.
31. Polypeptid ifølge krav 30, hvor E-peptidet er valgt fra en sekvens fra fig. 12A.
32. Polypeptid ifølge ethvert af kravene 28-32, hwor R68 eller D69 i precursorproteinet er deleteret eller muteret.
33. Fremgangsmåde til forøgelse af graden og/eller udstrækningen af vækst i et ikke-humant dyr, omfattende indgivelse af en virksom mængde af et polypeptid ifølge opfindelsen ifølge ethvert af kravene 1-32.
34. Fremgangsmåde ifølge krav 33, hvor det ikke-humane dyr er et kødproducerende dyr, omfattende svin, kvæg, får, fjerkræ og fisk.
35. Fremgangsmåde til forøgelse af effektiviteten af omdannelse af foder i kropsvæv i en ikke-humant dyr, omfattende indgivelse af en virksom mængde af et polypeptid ifølge opfindelsen ifølge ethvert af kravene 1-32.
36. Fremgangsmåde ifølge krav 35, hvor det ikke-humane dyr er et kødproducerende dyr omfattende svin, kvæg, får, fjerkræ og fisk.
37. Fremgangsmåde til forøgelse af mælkeproduktion hos mælkegivende ikke-humane dyr, omfattende indgivelse af en virksom mængde af et polypeptid ifølge opfindelsen ifølge ethvert af kravene 1-32.
38. Fremgangsmåde ifølge krav 37, hvor det ikke humane dyr er et mælkegivende dyr omfattende malkekvæg, svin, får og geder,
39. Fremgangsmåde til behandling af et ikke-humant dyr for hentæringssymptomer forbundet med kachexi, traumer eller andre indtagelsessygdomme, omfattende indgivelse af en virksom mængde af et polypeptid ifølge ethvert af kravene 1-32.
40. Fremgangsmåde ifølge krav 39, hvor det ikke-humane dyr er et husdyr omfattende hunde, katte og heste.
41. Fremgangsmåde til behandling af mælkegivende ikke-humane dyr til forbedring af neonatal sundhed, omfattende indgivelse af en virksom mængde af et polypeptid ifølge opfindelsen ifølge ethvert af kravene 1-32.
42. Fremgangsmåde ifølge krav 41, hvor det ikke-humane dyr er et mælkegivende dyr omfattende malkekvæg, svin, får og geder.
43. Anvendelse af polypeptidet ifølge ethvert af kravene 1-32 til fremstilling af en veterinær sammensætning til anvendelse ved en fremgangsmåde ifølge ethvert af kravene 33-42.
44. Anvendelse af polypeptidet ifølge krav 43, hvor den veterinære sammensætning er en stor oral dosis, et supplement til oralt foder eller supplemeent til fast foder.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81234906P | 2006-06-09 | 2006-06-09 | |
| US81234906 | 2006-06-09 | ||
| US86224406P | 2006-10-20 | 2006-10-20 | |
| US86224406 | 2006-10-20 | ||
| US89718707P | 2007-01-24 | 2007-01-24 | |
| US89718707 | 2007-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200900016A true DK200900016A (da) | 2009-01-06 |
Family
ID=38801859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07798148.8T DK2032155T3 (da) | 2006-06-09 | 2007-06-06 | Stabiliserede insulinlignende vækstfaktor-polypeptider |
| DK200900016A DK200900016A (da) | 2006-06-09 | 2009-01-06 | Stabiliserede insulinlignende vækstfaktorpolypeptider |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07798148.8T DK2032155T3 (da) | 2006-06-09 | 2007-06-06 | Stabiliserede insulinlignende vækstfaktor-polypeptider |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US8343918B2 (da) |
| EP (2) | EP2032155B1 (da) |
| JP (2) | JP2009539805A (da) |
| KR (1) | KR101459789B1 (da) |
| AR (1) | AR061242A1 (da) |
| AU (2) | AU2007257936B2 (da) |
| BR (2) | BRPI0712052A2 (da) |
| CA (2) | CA2653781A1 (da) |
| CL (1) | CL2007001614A1 (da) |
| CR (2) | CR10432A (da) |
| CY (1) | CY1116117T1 (da) |
| DK (2) | DK2032155T3 (da) |
| EC (1) | ECSP088949A (da) |
| ES (1) | ES2529261T3 (da) |
| GT (1) | GT200800273A (da) |
| HR (1) | HRP20150326T1 (da) |
| IL (1) | IL195156A (da) |
| JO (1) | JO2968B1 (da) |
| MA (1) | MA30503B1 (da) |
| MX (2) | MX2008015726A (da) |
| MY (1) | MY147856A (da) |
| NO (2) | NO20085183L (da) |
| NZ (2) | NZ572548A (da) |
| PE (1) | PE20080715A1 (da) |
| PL (1) | PL2032155T3 (da) |
| PT (1) | PT2032155E (da) |
| RU (1) | RU2477287C2 (da) |
| SI (1) | SI2032155T1 (da) |
| TN (1) | TNSN08509A1 (da) |
| TW (1) | TWI427084B (da) |
| UA (1) | UA97953C2 (da) |
| WO (2) | WO2007141309A2 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318355A1 (en) * | 2006-02-15 | 2009-12-24 | Chen Thomas T | Compositions and methods for promoting tissue repair and wound healing |
| KR101459789B1 (ko) * | 2006-06-09 | 2014-11-07 | 노파르티스 아게 | 안정화된 인슐린-유사 성장 인자 폴리펩티드 |
| JP5627571B2 (ja) | 2008-05-07 | 2014-11-19 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム標的化ペプチドおよびその使用 |
| EA201100741A1 (ru) * | 2008-11-10 | 2012-01-30 | Новартис Аг | Антитела к модифицированным пептидам ифр-1/е человека |
| WO2010088502A2 (en) * | 2009-01-30 | 2010-08-05 | The Regents Of The University Of California | Insulin-like growth factor signaling and integrin |
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| WO2011011072A2 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| DK2498796T3 (da) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | Behandling af hjertesygdom |
| JP2011160696A (ja) * | 2010-02-08 | 2011-08-25 | Novartis Ag | 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体 |
| AU2012220558A1 (en) | 2011-02-23 | 2013-08-22 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| US20140357558A1 (en) * | 2011-06-24 | 2014-12-04 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of spinal muscular atrophy |
| JP6472999B2 (ja) | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
| WO2014012025A2 (en) * | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Igf-1 proteins and therapeutic uses thereof |
| US10030063B2 (en) | 2012-12-18 | 2018-07-24 | Novartis Ag | Production of therapeutic proteins in genetically modified mammalian cells |
| PL2935320T3 (pl) * | 2012-12-18 | 2020-03-31 | Novartis Ag | Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu |
| HK1219280A1 (zh) | 2013-08-14 | 2017-03-31 | Novartis Ag | 治疗偶发性包涵体肌炎之方法 |
| US20160271265A1 (en) * | 2013-10-02 | 2016-09-22 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) * | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| ES2872998T3 (es) * | 2013-12-19 | 2021-11-03 | Puretein Bioscience Llc | Procedimientos de tratamiento de animales |
| CN105992951A (zh) | 2014-01-27 | 2016-10-05 | 诺华股份有限公司 | 预测肌萎缩的生物标志物、方法和用途 |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| WO2016126924A1 (en) * | 2015-02-04 | 2016-08-11 | Puretein Bioscience Llc | Methods for increasing performance characteristics in offspring |
| KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| LT3600415T (lt) | 2017-03-24 | 2025-12-29 | Novartis Ag | Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui |
| JP6691503B2 (ja) * | 2017-04-13 | 2020-04-28 | 任天堂株式会社 | ゲームプログラム、ゲーム処理制御方法、およびゲーム装置 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| WO2023145961A1 (ja) * | 2022-01-31 | 2023-08-03 | 国立大学法人信州大学 | ＩＧＦ１Ｒを標的とするｐｒｅ－ｐｒｏ前駆体型キメラ抗原受容体発現細胞 |
| CN119569848A (zh) * | 2024-11-22 | 2025-03-07 | 福建省农业科学院畜牧兽医研究所 | 一种鸭源igf2重组蛋白及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| ATE81779T1 (de) | 1985-08-22 | 1992-11-15 | Gropep Pty Ltd | Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren. |
| ATE116335T1 (de) | 1987-12-24 | 1995-01-15 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). |
| GB8819826D0 (en) * | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
| WO1993023067A1 (en) * | 1992-05-08 | 1993-11-25 | Thomas Jefferson University | Igf-1 analogs |
| AU1178395A (en) | 1993-11-12 | 1995-05-29 | North Shore University Hospital Research Corporation | Method of treating muscular dystrophy |
| WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| GB9605124D0 (en) * | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
| US7118752B2 (en) * | 1998-07-22 | 2006-10-10 | University Of Connecticut | Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I |
| AU762351B2 (en) * | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| GB9926968D0 (en) * | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
| GB0011278D0 (en) | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
| WO2002085923A2 (en) * | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| GB0426154D0 (en) * | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
| EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| JP4988599B2 (ja) | 2005-01-07 | 2012-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 |
| WO2006097682A1 (en) | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| AU2006224334A1 (en) | 2005-03-18 | 2006-09-21 | The Board Of Trustees Of The University Of Illinois | Mecano growth factor peptides and their use |
| US20090271875A1 (en) | 2005-03-31 | 2009-10-29 | Pioneer Corporation | Upgrade Module, Application Program, Server, and Upgrade Module Distribution System |
| KR101459789B1 (ko) | 2006-06-09 | 2014-11-07 | 노파르티스 아게 | 안정화된 인슐린-유사 성장 인자 폴리펩티드 |
-
2007
- 2007-06-06 KR KR1020087029888A patent/KR101459789B1/ko not_active Expired - Fee Related
- 2007-06-06 SI SI200731622T patent/SI2032155T1/sl unknown
- 2007-06-06 EP EP07798148.8A patent/EP2032155B1/en active Active
- 2007-06-06 AR ARP070102431A patent/AR061242A1/es unknown
- 2007-06-06 JP JP2009513697A patent/JP2009539805A/ja active Pending
- 2007-06-06 AU AU2007257936A patent/AU2007257936B2/en not_active Ceased
- 2007-06-06 RU RU2008151511/10A patent/RU2477287C2/ru not_active IP Right Cessation
- 2007-06-06 BR BRPI0712052-4A patent/BRPI0712052A2/pt not_active Application Discontinuation
- 2007-06-06 MX MX2008015726A patent/MX2008015726A/es active IP Right Grant
- 2007-06-06 CL CL200701614A patent/CL2007001614A1/es unknown
- 2007-06-06 UA UAA200814196A patent/UA97953C2/uk unknown
- 2007-06-06 AU AU2007255419A patent/AU2007255419A1/en not_active Abandoned
- 2007-06-06 MY MYPI20084827A patent/MY147856A/en unknown
- 2007-06-06 PE PE2007000699A patent/PE20080715A1/es not_active Application Discontinuation
- 2007-06-06 HR HRP20150326TT patent/HRP20150326T1/hr unknown
- 2007-06-06 NZ NZ572548A patent/NZ572548A/en not_active IP Right Cessation
- 2007-06-06 CA CA002653781A patent/CA2653781A1/en not_active Abandoned
- 2007-06-06 MX MX2008015657A patent/MX2008015657A/es not_active Application Discontinuation
- 2007-06-06 BR BRPI0712147-4A patent/BRPI0712147A2/pt not_active IP Right Cessation
- 2007-06-06 JP JP2009514507A patent/JP5290966B2/ja not_active Expired - Fee Related
- 2007-06-06 CA CA2654944A patent/CA2654944C/en not_active Expired - Fee Related
- 2007-06-06 JO JO2007215A patent/JO2968B1/en active
- 2007-06-06 TW TW096120340A patent/TWI427084B/zh not_active IP Right Cessation
- 2007-06-06 US US12/304,068 patent/US8343918B2/en not_active Expired - Fee Related
- 2007-06-06 ES ES07798148.8T patent/ES2529261T3/es active Active
- 2007-06-06 WO PCT/EP2007/055608 patent/WO2007141309A2/en not_active Ceased
- 2007-06-06 PL PL07798148T patent/PL2032155T3/pl unknown
- 2007-06-06 EP EP07729975A patent/EP2032154A2/en not_active Withdrawn
- 2007-06-06 WO PCT/US2007/070468 patent/WO2007146689A2/en not_active Ceased
- 2007-06-06 US US12/303,623 patent/US20100173839A1/en not_active Abandoned
- 2007-06-06 PT PT77981488T patent/PT2032155E/pt unknown
- 2007-06-06 NZ NZ572708A patent/NZ572708A/en not_active IP Right Cessation
- 2007-06-06 DK DK07798148.8T patent/DK2032155T3/da active
-
2008
- 2008-11-06 IL IL195156A patent/IL195156A/en not_active IP Right Cessation
- 2008-11-10 CR CR10432A patent/CR10432A/es unknown
- 2008-12-04 GT GT200800273A patent/GT200800273A/es unknown
- 2008-12-05 TN TNP2008000509A patent/TNSN08509A1/en unknown
- 2008-12-08 MA MA31459A patent/MA30503B1/fr unknown
- 2008-12-09 EC EC2008008949A patent/ECSP088949A/es unknown
- 2008-12-11 NO NO20085183A patent/NO20085183L/no not_active Application Discontinuation
- 2008-12-11 NO NO20085184A patent/NO20085184L/no not_active Application Discontinuation
-
2009
- 2009-01-06 DK DK200900016A patent/DK200900016A/da not_active Application Discontinuation
-
2012
- 2012-10-30 US US13/664,055 patent/US8722621B2/en not_active Expired - Fee Related
-
2014
- 2014-01-15 US US14/155,974 patent/US20170066808A9/en not_active Abandoned
-
2015
- 2015-03-13 CY CY20151100260T patent/CY1116117T1/el unknown
-
2016
- 2016-03-07 CR CR20160115A patent/CR20160115A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200900016A (da) | Stabiliserede insulinlignende vækstfaktorpolypeptider | |
| Lidfors | Cross-sucking in group-housed dairy calves before and after weaning off milk | |
| JP3884069B2 (ja) | 給餌効率を向上させるために使用されるｃｃｋ抗体 | |
| CN1184407A (zh) | 动物的应激反应调节剂 | |
| EP2134165B1 (en) | Compositions and methods including expression and bioactivity of bovine follicle stimulating hormone | |
| Mogensen et al. | Effect of space allowance in deep bedding systems on resting behaviour, production, and health of dairy heifers | |
| KR20090047392A (ko) | 번식 효율 개선을 위한 가축 관리 | |
| Tucker | Behaviour of cattle. | |
| Tucker | Behaviour of cattle. | |
| KR20170109570A (ko) | 자손에서의 성능 특성을 증가시키는 방법 | |
| Mosimanyana et al. | Feeding of crop residues to milking cows in small scale farms in Botswana | |
| Singaravadivelan et al. | Behaviours, health status and growth performance of crossbred jersey calves reared under different weaning system | |
| Weary et al. | Rethinking painful management practices | |
| Hoblet | Effects of nutrition on hoof health | |
| EP1946766B1 (en) | Reproductive disorder remedy | |
| Leech | Food losses through animal disease | |
| Tkachova | TECHNOLOGICAL AND CLIMATE FACTORS AFFECTING MILK QUALITY OF DAIRY CATTLE | |
| Vachkova et al. | Epidermal growth factor content in rabbit doe milk during the different lactation stages. | |
| Hristov et al. | The most significant predisposing factors and causes of lameness of dairy cows | |
| Klir et al. | Comparison of milk production traits by Istrian pramenka between conventional and organic systems in Slovenia | |
| McLeod et al. | Effect of anthelmintic and selenium drenching on live‐weight gain in young beef cattle | |
| Raziq et al. | Milk production potential of Kohi camels in Balochistan, Pakistan | |
| Venter | Angora producers: how to increase your kid yield | |
| Telezhenko et al. | Effect of different flooring systems on the claw horn growth and wear in dairy cows. | |
| Vestergaard et al. | Use of foster cows to produce rosé veal of spring-born dairy calves in an organic setting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |